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Abstract
The optimal blood pressure (BP) management in acute ischaemic stroke (AIS) and acute intracerebral haemorrhage
(ICH) remains controversial. These European Stroke Organisation (ESO) guidelines provide evidence-based recom-
mendations to assist physicians in their clinical decisions regarding BP management in acute stroke.The guidelines
were developed according to the ESO standard operating procedure and Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) methodology. The working group identified relevant clinical questions, per-
formed systematic reviews and meta-analyses of the literature, assessed the quality of the available evidence, and made
specific recommendations. Expert consensus statements were provided where insufficient evidence was available to
provide recommendations based on the GRADE approach. Despite several large randomised-controlled clinical trials,
quality of evidence is generally low due to inconsistent results of the effect of blood pressure lowering in AIS. We
recommend early and modest blood pressure control (avoiding blood pressure levels >180/105mmHg) in AIS patients
undergoing reperfusion therapies. There is more high-quality randomised evidence for BP lowering in acute ICH, where
intensive blood pressure lowering is recommended rapidly after hospital presentation with the intent to improve
recovery by reducing haematoma expansion. These guidelines provide further recommendations on blood pressure
thresholds and for specific patient subgroups.There is ongoing uncertainty regarding the most appropriate blood pres-
sure management in AIS and ICH. Future randomised-controlled clinical trials are needed to inform decision making on
thresholds, timing and strategy of blood pressure lowering in different acute stroke patient subgroups.
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Introduction
Elevated blood pressure levels (systolic blood pressure
140mmHg and/or diastolic blood pressure
90mmHg) are common in patients with acute ischae-
mic stroke (AIS) and acute intracerebral haemorrhage
(ICH), but the pathophysiology of the hypertensive
response is poorly understood.1 Despite considerable
research effort, the optimal post-stroke blood pressure
management in these conditions remains controversial
and unresolved. As randomised-controlled clinical
trials (RCTs) of this topic are limited and challenging,
clinical decisions are often made on the basis of obser-
vational studies that are prone to bias, confounding
and random error.2–5 Theoretical concepts and patho-
physiological arguments are used to defend arguments
for and against alteration of blood pressure in the set-
ting of acute stroke; to reduce the risk of stroke recur-
rence, cerebral oedema, reperfusion haemorrhage for
AIS patients after reperfusion therapies, and reduce
haematoma expansion and cerebral oedema in ICH;
to avoid impairment of cerebral perfusion to viable
ischaemic tissue in the presence of altered autoregula-
tion.6,7 Whilst most attention has been focused on the
avoidance of hypertension, drug-induced hypertension
has been proposed as a potential therapeutic strategy to
increase cerebral perfusion in some AIS patients.8
Although numerous observational studies have
shown that both extremely low and high blood pressure
levels are associated with worse outcomes in AIS and
ICH patients,9–12 there has been inconsistency in results
from multiple RCTs of different antihypertensive strat-
egies for acute stroke subtypes.
Here, we update previous guidelines from the
European Stroke Organisation (ESO) on the manage-
ment of acute blood pressure in AIS13 and ICH,14 this
including new RCTs and individual patient data meta-
analyses (IPDM) that have been published since 200813
and 201414 respectively. We review current evidence
and provide recommendations for blood pressure man-
agement (both blood pressure reduction and augmen-
tation) in patients with acute stroke; including
recommendations for blood pressure management in
the pre-hospital setting, according to eligibility for
reperfusion treatment in AIS and separately for
patients with acute ICH. Our goal was to facilitate
decision-making in these patient groups where there
is considerable ongoing uncertainty over optimal
post-stroke blood pressure management.
Methods
This guideline was initiated by the ESO and prepared
according to ESO standard operating procedures,15
which are based on the Grading of
Recommendations, Assessment, Development and
Evaluations (GRADE) system.16 The ESO Guidelines
Board and Executive Committee reviewed the intellec-
tual and financial disclosures of the module working
group (MWG) members (Table 1) and approved the
composition of the group, which was co-chaired by
the first (ECS) and last (GT) authors.
The MWG undertook the following steps:
1. Produced a list of topics of clinical interest to Guideline
users that were agreed by all MWG members, without
reference to blood pressure management for secondary
stroke prevention, in patients with transient ischaemic
attack (TIA), and in children with acute stroke.
2. Eight Patient Intervention Comparator Outcome
(PICO) were developed and agreed upon within
the MWG following a teleconference and e-mail
correspondence.
3. Produced a list of relevant outcomes for which the
MWG used the Delphi method to score their impor-
tance (mean score from 10 respondents on a scale of
1 to 9).
The list of outcomes in the AIS subgroup were:
• Mortality (90 days or end
of follow-up) Mean score: 8.8/9
• Functional outcome (90 days
or the end of follow-up) Mean score: 8.8/9
• Recurrent ischaemic stroke Mean score: 7.0/9
• Symptomatic ICH Mean score: 6.9/9
• Quality of life (90 days) Mean score: 6.4/9
• Neurological deterioration Mean score 5.5/9
(48 hours)
• Acute kidney injury Mean score 4.0/9
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The list of outcomes in ICH subgroup were:
• Mortality (90 days or Mean score: 8.9/9
end of follow-up)
• Functional outcome
(90 days or end of follow-up) Mean score: 8.9/9
• Haematoma expansion Mean score: 6.9/9
• Quality of life (90 days) Mean score: 5.4/9
• Neurological deterioration Mean score 6.4/9
(48 hours)
• Incident ischaemic stroke Mean score: 5.4/9
• Recurrent ICH Mean score: 5.2/9
• Acute kidney injury Mean score 4.2/9
Based on voting scores, functional outcome and
mortality were allocated highest priority for both AIS
and ICH and were the only outcomes considered in the
meta-analyses. The outcome of recurrent ischaemic
stroke was also of interest in the AIS subgroup, while
haematoma expansion was the outcome considered
important in the ICH subgroup. Unless specified
otherwise, ‘excellent’ and ‘good’ outcome were defined
as 3-month modified Rankin Scale (mRS) scores of 0–1
and 0–2, respectively. Unless specified otherwise, ‘any
better’ functional outcome corresponded to an ordinal
shift analysis of the mRS score at 3 months. For the
subgroup of patients with suspected stroke in the pre-
hospital setting we used the outcomes favoured in the
AIS subgroup since the aetiology in the majority
(80%-85%) of these patients is ischaemic. The
MWG formulated a list of PICO questions according
to the ESO Guideline SOP, which were reviewed and
subsequently approved by the ESO Guidelines Board
and Executive Committee.
4. The main recommendations were based on a sys-
tematic review of RCTs evaluating different blood
pressure management strategies in AIS and ICH
patients. The literature search was completed on
September 30, 2020. We conducted a systematic
review in all PICOs resulting in 35 different sets
of analyses. Details regarding the search strategies
Table 1. Continued.
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are provided in the Supplement. We also included
relevant literature published to February 27, 2021
in the final manuscript.
5. For each PICO question, a group consisting of
three to four MWG members was formed.
6. MWG members assigned to each PICO indepen-
dently screened the titles and abstracts of the pub-
lications identified by the electronic search and
assessed the full text of potentially relevant RCTs.
Where there were no RCT data available for a cer-
tain topic, systematic reviews of non-randomised
studies or key observational studies were identified
and considered.
7. Where appropriate, a random-effects meta-analysis
was conducted using Stata software version 11.0
(Statacorp), with results summarised as odds
ratios (ORs) and 95% confidence interval (CI).
Any heterogeneity across studies was assessed
using the I2 statistic, and heterogeneity was classi-
fied as moderate (I2 30%), substantial
(I2 50%), or considerable (I2 75%).17 The
Cochrane Collaboration risk of bias tool was
used for the risk of bias assessment.
8. The results of data analysis were imported into
the GRADEpro Guideline Development Tool
(McMaster University, 2015; developed by
Evidence Prime, Inc.). For each PICO question
and each outcome, the risk of bias was assessed
and quality of evidence rated as high, moderate,
low or very low based on the type of available evi-
dence (randomised or observational studies) and
considerations on inconsistency of results, indirect-
ness of evidence, imprecision of results, and risk of
bias.15,16 GRADE evidence profiles/summary of
findings tables were generated using GRADEPro.
9. Each PICO group addressed their respective ques-
tion by providing distinct sections. First, Analysis
of current evidence summarised current pathophys-
iological considerations and relative recommenda-
tions from other scientific societies related to that
specific question, followed by a summary and dis-
cussion of the results of the identified RCTs. Where
there was no RCT, the paragraph described the
results of systematic reviews of non-randomised
studies. Second, Additional information was added
when more details on RCTs referred to in the first
section were needed, to summarise results of obser-
vational studies, or to provide information on key
subgroup analyses of the included RCTs and on
ongoing or future RCTs. Third, Evidence-based
Recommendations were provided, these based on
the GRADE methodology. The direction, strength
and formulation of the recommendation were
determined according to the GRADE evidence
profiles and the ESO-SOP.15,16,18 These
recommendations do not apply to planned or
ongoing trials. Finally, according to the first
addendum to the ESO SOP, Expert Consensus
Statements were added whenever the PICO group
considered that there was insufficient evidence
available to provide Evidence-based
Recommendations where practical guidance is
needed for routine clinical practice. In that case,
a pragmatic suggestion was provided, with the
results of the votes of all MWG members (apart
from AL, a methodologist who contributed in lit-
erature search and data analysis) on this proposal.
Importantly, the suggestions provided in this par-
agraph should not be mistaken as evidence-based
recommendations but rather as the opinion of the
MWG members.
10. The Guideline document was subsequently
reviewed several times by all MWG members and
revised until a consensus was reached. Finally, the
Guideline document was reviewed and approved by
external reviewers and members of the ESO
Guidelines Board and Executive Committee.
Results
In patients with suspected acute stroke, does
pre-hospital blood pressure lowering with any
vasodepressor drug compared to no drug improve
outcome?
Analysis of current evidence
High blood pressure in patients with suspect stroke in
the ambulance is common, and blood pressure may
vary according to stroke subtype.19 High blood pres-
sure is associated with poor short- and long-term func-
tional outcome both patients with AIS and ICH.
Treatment-resistant very high blood pressure (>185/
110mmHg) is a contraindication to intravenous
thrombolysis (IVT),20 whereas blood pressure lowering
in acute ICH has been associated with improved func-
tional outcome and reduced haematoma expan-
sion.21,22 Blood pressure management is a relatively
low-cost treatment option feasible in the pre-hospital
setting, and may contribute to improved outcomes in
patients with suspected stroke.23 Current ESO and
European Academy of Neurology (EAN) guidelines
do not recommend blood pressure lowering in the
pre-hospital setting24 and the American Heart
Association (AHA)/American Stroke Association
(ASA) have no specific recommendations for blood
pressure management for patients with suspected
stroke in this setting.25
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The Rapid Intervention with Glyceryl Trinitrate in
Hypertensive Stroke trial (RIGHT) randomised 41
patients with suspected stroke (Face Arm Speech Test
score of 2 or 3) and systolic blood pressure 140mmHg
within 4 hours of symptom onset. The intervention,
transdermal glyceryl trinitrate (GTN), was administered
in the ambulance by trained paramedics. At 90days,
there was a significant improvement in the mRS with
a shift of 1 point in favour of treatment with GTN
(p¼ 0.04), but no significant difference in mortality
(GTN 4/25 vs no GTN 6/16, p¼ 0.15).26
The RIGHT-2 trial recruited 1149 patients with
suspected stroke (Fast Arm Speech Test scores 2 or
3) and systolic blood pressure 120mmHg) within
4 hours of symptom onset, according to a similar
intervention as the pilot trial. There were no differ-
ences in mRS scores (mRS> 2) in patients with a final
diagnosis of stroke (GTN 286/434 [68%] vs no GTN
282/418 [69%]; p¼ 0.55) nor in all included patients
(GTN 358/568 [66%] vs no GTN 373/581 [67%];
p¼ 0.88), nor in mortality.27
Two trials were included in a meta-analysis for the
outcome of death at three months,26,27 with no differ-
ence detected between any vasodepressor drug com-
pared to control (OR 0.74, 95%CI: 0.23 – 2.35
p¼ 0.61, I2¼ 63%) (Figure 1). There were also no dif-
ference in the endpoint of good functional outcome
(mRS 0–2 versus 3–6) between any vasodepressor
drug compared to control (OR 1.33, 95%CI; 0.59 –
3.01, p¼ 0.49, I2¼ 46%) (Figure 2).
Table 2 provides details regarding the safety and
efficacy of any vasodepressor drug compared with no
vasodepressor drug in patients with suspected stroke in
the pre-hospital setting.
Additional information
The Field Administration of Stroke Therapy-
Magnesium (FAST-MAG) randomised 1700 patients
in the ambulance with suspected stroke to intravenous
magnesium or placebo within 2 hours of symptom
onset. The trial evaluated the potential neuroprotective
effect of magnesium, which also has mild vasoactive
activities. There were no differences between the two
groups in the rates of good functional outcome (mRS
scores (0-2) at 3months (magnesium 449/857 [52%) vs
placebo 445/843 [53%]; p¼ 0.88) nor in mortality
(magnesium 132/857 [15%] vs placebo 131/843 [16%];
p¼ 0.95).28
The Paramedic Initiated Lisinopril for Acute Stroke
Treatment (PIL-FAST) trial randomised 14 patients
with unilateral arm weakness, systolic blood pressure
160mmHgwithin 3 hours of symptomonset to sublin-
gual lisinopril or control. Bloodpressurewas lower in the
lisinopril group on hospital admission. There was no dif-
ference in 1-weekmortality between the two groups (lisi-
nopril 1/6 [17%] vs placebo 1/8 [13%]).23 Since the trial
did not report mortality beyond 1week, we did not
include the trial in the meta-analysis.
In the subgroup of 145 patients included in the
RIGHT-2 trial with confirmed ICH after admission
Figure 1. Effect of pre-hospital blood pressure lowering by any vasopressor drug compared to no drug on mortality at three months
following symptom onset.
Figure 2. Effect of pre-hospital blood pressure lowering by any vasopressor drug compared to no drug on good functional outcome
(mRS scores 0–2) at three months following symptom onset.
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to hospital, GTN was associated with a worse shift in
the mRS scores (adjusted common OR 1.87, 95%CI
0.98–3.57; p¼ 0.058). There was no difference in
death at days 4 or 90.29 Prehospital blood pressure
lowering in the ambulance in patients with suspected
stroke is currently being tested in two RCTs.30,31
Recommendation
In patients with suspected stroke we suggest against routine
blood pressure lowering in the pre-hospital setting.
Quality of evidence: Moderate
Strength of recommendation: Weak #?
Expert consensus statement
Due to the potential harm in patients with intracerebral
haemorrhage prehospital treatment with glyceryl trinitrate
should be avoided. Vote 9 of 10.
In hospitalised patients with acute
ischaemic stroke not treated with
reperfusion therapies (intravenous
thrombolysis or mechanical
thrombectomy), does blood pressure
lowering with any vasodepressor drug
compared to no drug improve outcome?
Analysis of current evidence
Only a minority of patients with AIS receive reperfu-
sion therapy (intravenous alteplase) in Europe: the per-
centage ranges from 1% to 20% (mean 7.3%), with
even less receiving mechanical thrombectomy (MT)
(mean 1.9%).32 Based on pathophysiology, optimal
blood pressure management may be different in
patients who are not eligible for reperfusion treatment
with either IVT or MT; lowering blood pressure may
reduce the risk of haemorrhagic transformation and
oedema, whereas high blood pressure may protect the
brain by maintaining cerebral perfusion when autore-
gulation is partially impaired. Current European13 and
AHA/ASA25 guidelines suggest a cautious approach to
hypertension management in those with AIS not eligi-
ble for IVT or MT, recommending against aggressive
blood pressure lowering in most patients during the
initial 24 hours unless blood pressure levels are
extreme, or there is a concomitant specific situation
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Data from 18 RCTs were considered in the analysis
of the effect of blood pressure lowering treatment on
death and/or disability.27,33–50,51,52 Seven included
patients with ICH but reported results separately for
ICH and AIS subgroups.27,37,44,45,47,50,51,52 One trial
did not discriminate between AIS and ICH34 but was
included based on the assumption that AIS contributed
to the majority of patients. Three trials included
patients who received IVT, but the proportion receiv-
ing IVT was low, and the results were available sepa-
rately for subgroups according to IVT either in the
main paper, or in subsequent post hoc analyses.27,37,45
Notably, the majority of studies excluded patients with
extremely high systolic blood pressure levels
(>220mmHg) and many included patients up to 72
hours of symptom onset.
Most of the patients were recruited from the three
RCTs described below:
The Scandinavian Candesartan Acute Stroke Trial
(SCAST) recruited 2029 patients with AIS (n¼ 1733)
and ICH (n¼ 274) and systolic blood pressure
140mmHg within 30 hours of onset and compared
treatment with candesartan for seven days with placebo
on co-primary end points at six months.45 Eight per-
cent of patients with AIS received IVT. Blood pressure
was lower in the treatment group at day 7 (5/
2mmHg difference in systolic and diastolic blood
pressures). There were neutral effects on the two co-
primary endpoints: 1) poor functional outcome at six
months (ordinal shift on mRS) and 2) composite out-
come of vascular death, myocardial infarction or stroke
during the six months follow-up period. There were no
significant differences between the candesartan and
placebo groups in mortality, functional outcome or
recurrent ischaemic stroke in the subgroup of 1733
patient with AIS.52
The Efficacy of Nitric Oxide in Stroke trial (ENOS)
randomised 4011 patients with AIS (n¼ 3342), includ-
ing 225 who received IVT, or ICH (n¼ 629) and sys-
tolic blood pressure 140–220mmHg to transdermal
GTN patches (5mg) or placebo within 48 hours of
onset for 7 days.37 In a partial factorial design, those
on pre-existing anti-hypertensive drugs were rando-
mised to stop or continue their medication. Blood pres-
sure was significantly lower in the GTN treatment
group at 24 hours (-7/-3mmHg difference) but there
was no significant difference after day 3. In the overall
patient population (AIS and ICH combined) the pri-
mary outcome (worse outcome on mRS scores at
90 days, shift analysis) was neutral for GTN versus pla-
cebo (adjusted common OR 1.01, 95% CI 0.91 to 1.13,
p¼ 0.83), with no significant interaction between
stroke type (AIS versus ICH) and effect of treatment
on outcome in a pre-specified subgroup analysis.
The ChinaAntihypertensive Trial in Acute Ischaemic
Stroke (CATIS) recruited 4071 patients with AIS (not
treated with IVT) and a systolic blood pressure ranging
between 140–220mmHg within 48 hours of symptom
onset.35 The study compared targeted blood pressure
lowering (10 to 25% systolic blood pressure reduction
in 24 hours) with either intravenous angiotensin recep-
tor inhibitors (ACEi) (first line), oral calcium channel
antagonists (CCB) (second line), or oral diuretics to con-
trol.Mean systolic blood pressure was lower in the treat-
ment group (9.1mmHg at 24 hours). There was no
significant effect on functional outcome (mRS 3) at
14 days or at 90 days.
All the other included studies reported similarly neu-
tral results.
In analyses of RIGHT-2 limited to 580 patients with
AIS, there was no evidence of an effect of GTN on
functional outcome at 90 days compared with sham
(worse outcome on mRS scores at 90 days, shift analy-
sis); adjusted common OR (1.15 [0.85–1.54];
p¼ 0.36).27
A post hoc subgroup analysis of the Prevention
Regime for Effectively Avoiding Second Strokes
(PRoFESS) trial examined the effect of adding the
angiotensin receptor blocker telmisartan versus place-
bo to standard antihypertensive treatment in 1360
patients with mild AIS within 72 hours of onset.
Telmisartan produced a modest lowering of blood
pressure, without increase in adverse events, but there
was no effect on poor functional outcome, mortality,
stroke recurrence or cardiovascular events. Again, the
cohort had mild neurological severity (median
National Institutes of Health Stroke Scale (NIHSS)
score 3), and treatment initiated rather late (average
58 hours after symptom onset).43
In a comparison of amlodipine or irbesartan versus
control in 320 AIS patients< 48 hours of onset, the
results for effect on poor functional outcome (mRS
3) favoured treatment (32.1% in treatment group
versus 45.0% in control group, p¼ 0.018).42
Conversely, Intravenous Nimodipine West European
Stroke Trial (INWEST), comparing the effect of nimo-
dipine (1 or 2mg IV for 5 days then 120mg orally) to
placebo in 265 AIS patients reported poorer functional
(according to Barthel Index) and neurological out-
comes (according to the Orgogozo scales) in the 2mg
treatment group versus placebo at 21 days (primary
efficacy time point) and at 24weeks.40
Eighteen trials were included in the meta-analysis for
the effect of blood pressure lowering on mortality at 3–
6months following symptom onset.27,33–40,42–50,52, 53 No
statistically significant effect was found; OR 1.00 (95%
CI: 0.84–1.19), p¼ 0.98, I2¼ 35% (Figure 3). Twelve
studies were included in the meta-analysis for the
8 European Stroke Journal 0(0)
effect of blood pressure lowering on improved function-
al outcome (mRS scores 0 to 2 at three to six months
following symptom onset; Figure 4). There was no sta-
tistically significant difference between the use of any
vasodepressor drug compared with control: (OR 0.98
95%CI: 0.85–1.12, p¼ 0.72, I2¼ 35%).27,35,38,41-47,50,53
Table 3 provides details regarding the safety and
efficacy of any vasodepressor drug compared with no
vasodepressor drug in patients with AIS not treated
with reperfusion therapies (IVT and/or MT).
Additional information
We hypothesise that factors other than blood pressure
may influence the treatment effect on outcomes, these
including drug class, blood pressure target, timing of
Figure 3. The effect of blood pressure lowering with any vasodepressor drug compared with no drug on mortality at three to six
months following symptom onset in patients with acute ischaemic stroke not treated with reperfusion therapies.
Figure 4. The effect of blood pressure lowering with any vasodepressor drug compared with no drug on good functional outcome
(mRS scores 0–2) at three to six months following symptom onset in patients with acute ischaemic stroke not treated with reper-
fusion therapies.
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treatment, underlying stroke aetiology, premorbid
blood pressure levels, and magnitude and rate of
blood pressure lowering. Data from the included stud-
ies regarding these variables are conflicting. When con-
sidering drug class: ACEi appear safe but did not
influence outcomes;35,51 RCTs using ARBs for blood
pressure reduction report conflicting results.45,46,48
Candesartan showed promising effects in a pilot
trial,48 but SCAST was neutral and if anything, fav-
oured placebo;45 the Valsartan Efficacy oN modesT
blood pressure Reduction in acute ischaemic stroke
(VENTURE) trial was neutral for functional outcome
but reported significantly more early neurological dete-
rioration among patients in the valsartan group;46 the
low dose BEta blockade in acute Stroke Trial (BEST)
reported increased early death in those randomised to
beta-blocker versus control (though this was minimal,
and did not reach significance in adjusted analyses),34
and in the Controlling Hypertension and Hypotension
Immediately Post Stroke (CHHIPS) trial,51 labetalol
was safe. Results from small RCTs of CCBs have pro-
duced mixed results: some favoured placebo,40,41 but
others have been neutral.33 Small and larger RCTs in
Nitric Oxide (NO) donors have reported safety with
GTN but no significant effect on functional
outcome.29,37,44,47
Premorbid and initial blood pressure level and
blood pressure targets may also be of importance.1
Most RCTs excluded AIS patients with extremely ele-
vated systolic blood pressure (>220mmHg), and thus
the effects of blood pressure lowering in this group
are unknown. Owing to heterogeneity in terms of
blood pressure targets among studies, no robust con-
clusions can be drawn as to the optimal blood pres-
sure target, though avoiding large drops in blood
pressure during the first 24 hours seems reasonable
given the negative effects reported on some outcomes
in trials of intravenous CCBs with large (>20%)
reduction in blood pressure.40,41,49,53 Time to treat-
ment may have an effect and has varied considerably
across RCTs (<4 hours to 5 days). In the ENOS
patient subgroup treated within 6 hours54 treatment
with GTN was associated with significantly improved
functional outcome, and among a similar group of
participants in SCAST there was a non-significant
benefit on the composite vascular endpoint in those
treated< 6 hours.55 In CATIS, subgroup analysis
showed a reduction in poor functional outcome in
those randomised later (>24 hours) from stroke
symptom onset.35 In RIGHT-2, where treatment
was initiated within 4 hours of onset, GTN was asso-
ciated with a non-significant trend for a worse func-
tional outcome;27 this tendency towards harm was
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(<1 hour), and severe stroke (Glasgow Coma
Scale< 12, NIHSS >12).27
Neurological severity and subtype may alter the
effect of treatment. In a secondary subgroup analysis
of patients with AIS included in SCAST there was a
benefit of treatment with candesartan in larger (total
and partial anterior circulation), but not smaller (lacu-
nar) AIS,52 as shown in another study.56 The presence
of large vessel occlusion and significant carotid artery
stenosis may influence the effect of blood pressure low-
ering treatment, although data are partly conflicting: a
pre-specified subgroup analysis from SCAST of AIS
patients with carotid imaging (n¼ 993) showed that
those with severe stenosis (70%) treated with cande-
sartan had a trend towards increased risk of stroke
progression and poor functional outcome (ordinal
shift on the mRS).57 Conversely, in ENOS, GTN was
shown to be safe across all levels of ipsilateral carotid
stenosis among participants with carotid imaging data
(n¼ 2038).58
We considered a 2014 Cochrane review relevant to
this topic.6 In the subgroup of 11,015 patients with AIS
there was no benefit of any vasodepressor drug com-
pared with control on the outcome of death and depen-
dency (as reported in the individual trials): OR¼ 1.00
(95%CI: 0.92–1.08). Furthermore, no differences in
treatment effect were observed in subgroups according
to drug class, stroke location (cortical versus subcorti-
cal), or blood pressure target used. CCBs, ACEi, ARB,
beta-blockers and NO donors all lowered blood
pressure.6
Recommendations
In hospitalised patients with acute ischaemic stroke and
blood pressure< 220/110mmHg not treated with intrave-
nous thrombolysis or mechanical thrombectomy, we suggest
against the routine use of blood pressure lowering agents at
least in first 24 hours following symptom onset, unless this is
necessary for a specific comorbid condition.
Quality of evidence: Moderate
Strength of recommendation: Weak #?
Expert consensus statement
In patients with acute ischaemic stroke not treated with
intravenous thrombolysis or mechanical thrombectomy
and blood pressure >220/120mmHg, careful blood pres-
sure reduction (<15% systolic blood pressure reduction
in 24 hours) is reasonable and likely to be safe. No specific
blood pressure lowering agent can be recommended. Vote
10 of 10.
In hospitalised patients with acute
ischaemic stroke and undergoing
intravenous thrombolysis (with or without
mechanical thrombectomy), does blood
lowering therapies compared to control
improve outcome?
Analysis of current evidence
Based on data from small, uncontrolled, non-
randomised pilot studies,59–61 elevated systolic and dia-
stolic blood pressure levels before (>185/110mmHg)
and during (>180/105mmHg) alteplase infusion of
AIS patients are contraindications to IVT based upon
the protocol for the original National Institute of
Neurological Diseases and Stroke (NINDS)-recombi-
nant tissue plasminogen activator (rt-PA) Stroke
Study.62 AHA/ASA and ESO guidelines endorse
these thresholds and advocate against treating AIS
patients with intravenous IVT, when blood pressure
is uncontrolled before or during thrombolysis
treatment.13,20,25
There are no randomised data to support these rec-
ommended blood pressure thresholds, and since elevat-
ed blood pressure is common in patients with AIS,63
IVT can be delayed or even denied in a substantial
number of patients whose blood pressure is above
this threshold and unresponsive to antihypertensive
treatment.64 In addition, there is appropriate concern
that aggressive blood pressure reduction, may reduce
viable penumbral tissue, result in expansion of the cere-
bral infarction and contribute to neurological deterio-
ration.64–66
Conversely, evidence from large, non-randomised
real world evidence studies and meta-analyses suggest
that elevated blood pressure levels before or during
IVT may be related to adverse clinical and imaging
outcomes including a higher risk of symptomatic intra-
cranial haemorrhage (sICH), a lower likelihood of
complete recanalisation and three-month good func-
tional outcome (mRS scores of 0–2) or three-month
functional improvement (1 point decrease across all
mRS grades on shift analyses).67–72 Additionally, in a
post-hoc analysis of the second European Cooperative
Acute Stroke Study (ECASS), increasing baseline,
maximum and mean (per 10mmHg) systolic blood
pressure levels were associated with a higher risk of
parenchymal haemorrhage during the 7 first days
after symptom onset in AIS.73 Similarly, in a post-
hoc analysis of third International Stroke Trial, the
odds of sICH increased by 10% (95%CI: 2–19%) for
each 10mmHg increase in baseline systolic blood pres-
sure, after adjustment for baseline stroke severity.74
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Many of these have studies illustrated a linear relation-
ship between increasing systolic or diastolic blood pres-
sure levels and the likelihood of sICH and of death or
dependency.70–74 They have also indicated that inten-
sive blood pressure control (below the recommended
levels of 180/105mmHg) during or after alteplase is
safe, and may further improve clinical outcomes and
reduce the rates of any or symptomatic intracranial
bleeding.67,75,76
There is no randomised evidence of the safety and
efficacy of blood pressure lowering therapies in AIS
patients treated with IVT that exceed guideline-
recommended blood pressure thresholds (>185/
110mmHg before alteplase bolus and >180/
105mmHg during and 24 hours after alteplase infu-
sion).13,20,25 However, there is considerable observa-
tional data showing that blood pressure protocol
violations are common among AIS patients treated
with IVT.67,77,78 In particular, a single-centre observa-
tional study reported that pre-treatment blood pressure
violations (>185/110mmHg) occurred in 12% of AIS
treated with IVT in everyday clinical practice and were
independently associated with higher likelihood of
sICH (OR: 2.59, 95%CI: 1.07–6.25).79 Moreover, in a
recent retrospective analysis of the Safe
Implementation of Treatments in Stroke (SITS) throm-
bolysis registry in regard to 11 off-label criteria related
to the European license for alteplase, elevated pre-
treatment blood pressure levels represented the only
off-label criterion that was independently associated
with a higher odds of sICH (OR: 1.39; 95%CI: 1.08–
1.80).77 Finally, a post-hoc analysis of a phase III RCT
of sono-thrombolysis that implemented a robust blood
pressure control protocol using serial blood pressure
recordings before during and after alteplase infusions
reported a high rate (34%) of blood pressure excur-
sions above the prespecified thresholds among AIS
patients treated with IVT. Most notable was that
blood pressure excursions above guideline thresholds
were associated with adverse clinical (neurological
worsening at 24 hours, functional dependence or
death at 3months) and imaging (any ICH at
24 hours) outcomes.78 The heterogeneity of the study
populations needs to be considered when interpreting
these results: patients had different AIS subtypes (large
vessel occlusion vs. lacunar stroke), different medical
histories (with or without history of hypertension) and
received different blood-pressure lowering therapies (b-
blockers vs. calcium channel blockers vs. central acting
antihypertensives). Finally, no specific antihypertensive
agent has been tested for controlling elevated blood
pressure levels (exceeding the recommended thresholds
before or during IVT for AIS).
The Enhanced Control of Hypertension and
Thrombolysis Stroke Study (ENCHANTED) investi-
gated the safety and efficacy of blood pressure lowering
strategies in AIS patients treated with IVT according to
guideline criteria (blood pressure levels< 185/
110mmHg).80 2196 patients with systolic blood
pressure> 150mmHg who were eligible for IVT with
alteplase were randomised to intensive blood pressure
lowering (target systolic blood pressure 130–
140mmHg within 1 hour) or to a standard target sys-
tolic blood pressure (<180mmHg), and for mainte-
nance of such levels over 72 hours. Mean systolic
blood pressure over 24 hours was 144 10mmHg in
the intensive group and 150 12mmHg in the control
group.80 Functional outcome at 90 days did not differ
between groups (unadjusted common OR per 1-point
improvement across all mRS scores: 1.01, 95%CI:
0.87–1.17, p¼ 0.87). However, fewer patients in the
intensive group (14.8%) than in the control group
(18.7%) had any ICH (OR 0.75, 0.60–0.94, p¼ 0.01).
Blood pressure reduction was also associated with a
non-significant decrease in type 2 parenchymal hae-
morrhage (OR 0.71, 95%CI 0.50–1.01, p¼ 0.05).80
The health-related quality of life was assessed as an
overall health utility score (EQ-5D) and no differences
were observed between the two treatment groups.80
Certain methodological concerns need to be taken
into account when interpreting ENCHANTED find-
ings.81 First, the study design was open-label and
blinded-endpoint adjudication. Second, the mean dif-
ference in systolic blood pressure levels during the
first 24 hours between the active and control treat-
ment group was modest differing by< 7mmHg
rather than the planned 15mmHg; this may have
limited the possibility to detect significant treatment
effects between groups. Third, included patients
already had blood pressure controlled below the
185/110mmHg thresholds and may have received
blood pressure lowering treatment prior to inclusion.
Fourth, almost three quarters of randomised patients
were from Asia where the pattern of cerebrovascular
disease differs from the West. Finally, advanced
imaging was not included in the selection of patients,
and thus the potential of exclusion of patients with
higher risk of sICH who may have benefited the
most from intensive blood pressure lowering treat-
ment strategies.
Table 4 provides details regarding the safety and
efficacy of intensive blood pressure lowering (target
systolic blood pressure 130–140mmHg within 1 hour)
compared to guideline-recommended blood pressure
levels (<180mmHg) over 72 hours following symptom
onset in AIS patients receiving IVT.
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Additional information
The ENCHANTED trial observed no significant het-
erogeneity of the treatment effect (shift on 3-month
mRS score) in subgroups including demographics
(age, sex, ethnicity), pre-treatment with antiplatelets,
dose of alteplase (low vs. standard), stroke severity
stratified by NIHSS scores and stroke subgroups
where large vessel occlusion might be anticipated,
AIS subtypes classified on the basis of clinician diag-
nosis of large vessel atherosclerosis, cardioembolism
or lacunar stroke.80,82 Notably, in the prespecified
subgroup analysis of severe stroke defined by com-
puted tomography or magnetic resonance angiogram
confirmation of large vessel occlusion, receipt of
endovascular therapy, final diagnosis of large artery
atherosclerotic disease, or high (>10) baseline NIHSS
score there was no significant difference in the prima-
ry outcome of death or disability at three months in
the two treatment arms. However, intensive blood
pressure lowering significantly increased three-
month mortality (OR 1.52, 95%CI: 1.09–2.13;
p¼ 0.014) compared with guideline blood pressure
lowering, despite significantly lower clinician-
reported ICH (OR0.63, 95%CI: 0.43–0.92;
p¼ 0.016).83 The findings of the aforementioned
post-hoc analysis may only serve for hypothesis gen-
eration and deserve further validation in future
RCTs.
A subgroup analysis of the ENOS trial within
48 hours of stroke onset compared GTN to no GTN
in 425 AIS patients presenting with elevated systolic
blood pressure levels (140–220mmHg) who also
received treatment with intravenous alteplase.37 A
total of 204 and 221 patients were randomised to
active and control groups respectively. GTN was not
associated with improved three-month functional out-
come compared to placebo (unadjusted common OR
per 1-point worsening across all mRS scores at three
months: 0.93, 95%CI: 0.66–1.30).37
An individual patient data meta-analysis of different
RCTs evaluating the safety and efficacy of NO for
blood pressure management in acute stroke has
reported that among 98 AIS patients treated with
IVT, GTN was associated with improved functional
outcomes at three months compared to placebo (unad-
justed common OR per 1-point worsening across all
mRS grades: 0.32, 95%CI: 0.15–0.69).84 However,
this was not confirmed in the RIGHT-2 trial, although
the GTN group had a trend towards less haemorrhagic
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Recommendations
1. In patients with acute ischaemic stroke undergoing treat-
ment with intravenous thrombolysis (with or without
mechanical thrombectomy) we suggest maintaining
blood pressure below 185/110mmHg before bolus and
below 180/105mmHg after bolus, and for 24 hours after
alteplase infusion. No specific blood pressure-lowering
agent can be recommended.
Quality of evidence: Very low
Strength of recommendation: Weak "?
2. In patients with acute ischaemic stroke undergoing treat-
ment with intravenous thrombolysis (with or without
mechanical thrombectomy) we suggest against lowering
systolic blood pressure to a target of 130–140mmHg
compared to <180mmHg during the first 72 hours fol-
lowing of symptom onset.
Quality of evidence: Moderate
Strength of recommendation: Weak #?
In patients with acute ischaemic stroke
caused by large vessel occlusion and
undergoing mechanical thrombectomy
(with or without intravenous
thrombolysis), does blood pressure
lowering with any vasodepressor drug
compared to no drug improve outcome?
Analysis of current evidence
Despite MT becoming standard of care for patients
with AIS due to large vessel occlusion of the anterior
circulation over the last year,85–87 approximately 46%
of patients with successful reperfusion die or are left
disabled following the procedure.88 Blood pressure
management in the acute/subacute setting following
recanalisation is a potential modifiable determinant
of functional improvement in this population.
However, data regarding the optimal blood pressure
management for AIS undergoing successful MT is
scarce89 and there is no clear consensus over the inten-
sity of blood pressure (lowering or enhancement)
before, during or after the MT.
Current AHA/ASA guidelines advocate thresholds
of systolic blood pressure 180mmHg and diastolic
blood pressure 105mmHg during and for the first
24 hours following MT,25 which have been arbitrarily
adopted based on evidence regarding blood pressure
management in the setting of IVT for AIS. The ratio-
nale of this recommendation is to avoid reperfusion
haemorrhages associated with elevated blood pressure
levels before, during and after MT for large vessel
occlusion.
Current MT guidelines from the ESO and European
Society for Minimally Invasive Neurological Therapy
(ESMINT) recommend systolic and diastolic blood
pressure levels< 180/105mmHg during and 24 hours
after MT and specify the importance of avoiding
drops in systolic blood pressure during the procedure.18
No specific blood pressure-lowering drug has been rec-
ommended. The quality of evidence is graded as low/
very low and strength of recommendation is weak in
both American25 and European18 recommendations.
The Society for Neuroscience in Anesthesiology and
Critical Care Expert Consensus Statement, recommend
that systolic blood pressure should be maintained
>140mmHg (fluids and vasopressors)
and< 180mmHg (with or without IVT), and diastolic
blood pressure< 105mmHg (class IIa, level of evi-
dence B) during endovascular treatment for AIS.90
There is a paucity of RCT data regarding the poten-
tial safety and efficacy of blood pressure lowering ther-
apies in MT-treated AIS patients with large vessel
occlusion that receive endovascular reperfusion thera-
pies. Most large vessel occlusion patients enrolled in
the RCTs within 6 hours of symptom onset had
received IVT before MT and the trial protocols stipu-
lated management according to local guidelines with
systolic or diastolic blood pressure levels 180/
105mmHg during and for 24 hours after the
procedure.
Observational evidence. Nevertheless, there are observa-
tional data indicating that extremely high systolic and/
or diastolic blood pressure levels (>220/120mmHg)
before MT for large vessel occlusion stroke are associ-
ated with worse clinical and imaging outcomes includ-
ing higher rates of sICH, mortality and functional
dependence.91–94
There are also observational data indicating that
hypotension is frequent during MT, can mainly be
explained by sedation modality (general anaesthesia
in particular) and appears to be associated with infarct
expansion and worse functional outcomes at three
months.95 An analysis of individual patient data from
3 RCTs (SAGA Collaborators) reported that both low
(<70mmHg) and high (>90mmHg) mean arterial
blood pressure levels during MT were associated with
worse functional outcomes at three months.96 Also, a
10% mean arterial blood pressure drop from baseline
during MT for AIS has been related to worse 3-month
functional outcomes regardless of sedation modality.97
Other observational studies and meta-analysis also
showed that mean arterial blood pressure falls 10%
during the endovascular procedure, intra-procedural
mean arterial blood pressure levels< 70mmHg for a
duration of 10min and mean arterial blood
pressure< 100mmHg before recanalisation are
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associated with adverse clinical outcomes in MT-
treated patients.98–100 These observations support the
hypothesis that a decrease in systemic blood pressure
may lead to hypoperfusion of ischaemic penumbra and
cause an increase in final infarction sizes.99,100
There are accruing observational evidence that
extremely elevated systolic and/or diastolic blood pres-
sure levels after MT for large vessel occlusion stroke
appear also to be associated with worse clinical and
imaging outcomes including higher rates of sICH, mor-
tality and functional dependence and this association
may be mediated by recanalisation status following
MT.91,101–104
Moreover, increased systolic blood pressure vari-
ability appears to be associated with adverse clinical
outcomes in large vessel occlusion patients treated
with MT independent of blood pressure levels.105
However, the heterogeneity of study populations
needs to be considered when interpreting these results
according to recanalisation status (complete versus
incomplete or no recanalisation), different blood pres-
sure parameters (systolic/diastolic blood pressure vs.
mean arterial blood pressure), medical history (hyper-
tension, cardiac disease), reperfusion strategy (direct
thrombectomy vs. bridging therapy with IVT and
MT) and different blood pressure lowering agents
(b-blockers vs. CCBs vs. centrally acting
antihypertensives).
Randomised evidence. There is one pilot RCT assessing
the feasibility of differential systolic blood pressure tar-
geting during MT for anterior circulation ischaemic
stroke. This trial randomly assigned 51 patients to
receive either standard or augmented systolic blood
pressure management from the start of anaesthesia to
recanalisation of the target vessel.106 There were no
safety concerns with trial procedures and all feasibility
targets were achieved.
Further randomised evidence on the intra-
procedural management of blood pressure during MT
will be provided by an ongoing explorative single-
centre RCT with a PROBE (parallel-group, open-
label randomised controlled trial with blinded endpoint
evaluation) design.107 In the control group, intraproce-
dural systolic blood pressure target range is
140–180mmHg. The intervention group is the individ-
ualised approach, which is maintaining the intraproce-
dural systolic blood pressure at the level on
presentation (10mmHg). The primary endpoint is
the 90-day mRS score dichotomised by 0–2 (good func-
tional outcome) to 3–6 (poor functional outcome).
Secondary endpoints include early neurological
improvement, infarction size, and systemic physiology
monitor parameters. Another ongoing multicentre
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individualised approach of blood pressure management
during MT.108 Patients randomised to the intervention
group will be treated with an individualised approach,
which is maintaining mean arterial blood pressure
during MT within 10% of the first mean arterial
blood pressure measurement before MT. In the control
group, the intraprocedural systolic blood pressure
target range will range between 140–180mmHg. The
primary endpoint is good functional outcome at
90 days (mRS scores of 0–2). Secondary endpoints
include early neurological improvement, excellent out-
come, infarct size, systemic physiology monitor param-
eter, sICH rates and mortality at 3months.
Table 5 summarises the design of five RCTs that eval-
uate different blood pressure targets below the pre-
specified cut-off of 180/105mmHg after the end of
MT.109–112 The only completed RCT is the Blood
Pressure Target in Acute Stroke to Reduce
Haemorrhage After Endovascular Therapy
(BP-TARGET) trial, a multicentre, prospective, rando-
mised, controlled, open-label, blinded endpoint clinical
trial conducted in France.113,114 The study enrolled AIS
patients with large vessel occlusion in the anterior circu-
lation who had successful reperfusion (defined as mod-
ified Thrombolysis In Cerebral Infarction (mTICI)
grades of 2 b or 3) following MT. The enrolled patients
were randomly assigned, in a 1:1 ratio, to have intensive
(systolic blood pressure target 100–129mmHg) or a
conservative (systolic blood pressure target 130–
185mmHg) blood pressure control in the following
24 hours, with the primary efficacy endpoint of radio-
graphic intraparenchymal haemorrhage at 24–36 hours
and the primary safety endpoint of hypotension occur-
rence. Secondary endpoints included the rate of the
sICH, the overall distribution of the mRS scores at
90 days, good functional outcome (90–day mRS scores
of 0–2), functional improvement (90-day decrease by 1
point across all 90-day mRS grades), infarct volume at
follow-up CT scan at 24–36 h, change in NIHSS-scores
at 24 hours, and all-cause mortality at 90 days. A total of
158 and 160 patients were randomised to the intensive
and conservative systolic blood pressure groups respec-
tively, with similar proportions of the primary endpoint
(any ICH: 42% in the intensive group vs. 43% in the
conservative group) and hypotension in the two treat-
ment groups (8% in the intensive group vs. 3% in the
conservative group). All secondary endpoints including
three-month functional improvement (common OR for
1-point improvement across all mRS categories: 0.86;
95%CI: 0.57–1.28), three-month good functional out-
come (mRS scores 0–2; 44% vs. 45%) and three-
month mortality (19% vs. 14%) were similar in the
two treatment groups.113 The main methodological
shortcoming of this RCT included: (i) modest systolic
blood pressure difference (10mmHg) between the rand-
omised groups; (ii) one third of the individuals in the
conservative arm having systolic blood pressure
measurements< 130mmHg; (iii) moderate sample
size; (iv) primary endpoint being imaging, rather than
clinical, (v) non-invasive modality of blood pressure
assessment every 15minutes for the first 2 hours, then
every 30minutes for 6 hours and every 1 hour for the
remaining 16 hours.
Table 6 provides details regarding the safety and
efficacy of reducing systolic blood pressure
<130mmHg in anterior circulation large vessel occlu-
sion during the first 24 hours following successful MT.
Additional information
Two protocols of RCTs evaluating the safety and effi-
cacy of MT compared to standard therapy in AIS
patients with anterior circulation large vessel occlusion
have provided additional recommendations regarding
optimal blood pressure management before and after
the endovascular procedure. The ESCAPE
(Endovascular Treatment for Small Core and
Proximal Occlusion Ischaemic Stroke) trial protocol
stated that systolic blood pressure 150mmHg is
probably useful in promoting and keeping collateral
flow adequate, while the artery remained occluded,
and that controlling blood pressure once reperfusion
has been achieved and aiming for a normal blood pres-
sure for that individual was sensible.115 Labetalol or an
intravenous beta-blocker such as metoprolol in low
doses were recommended for post-procedural blood
pressure management.115 The DAWN (Clinical
Mismatch in the Triage of Wake Up and Late
Presenting Strokes Undergoing Neurointervention
With Trevo) trial protocol recommended maintaining
systolic blood pressure< 140mmHg in the first
24 hours in subjects who were reperfused after MT.116
Three RCTs investigating the optimal anaesthesia
management (conscious sedation vs. general anaesthe-
sia) of large vessel occlusion patients treated with MT
have suggested specific systolic blood pressure ranges
during the procedures.117–119 The advocated intrapro-
cedural systolic blood pressure range until reperfusion
was 140–160mmHg in SIESTA (Sedation vs.
Intubation for Endovascular Stroke TreAtment)
trial,117 140–180mmHg in ANSTROKE (Anaesthesia
During Stroke) trial118 and >140mmHg in GOLIATH
(General Or Local Anaesthesia in Intra Arterial
THerapy) trial.119
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Large vessel occlusion patients who undergo suc-
cessful reperfusion documented as mTICI grades 2 b
following endovascular therapy display spontaneous
blood pressure drop due to potential earlier reperfu-
sion of the ischaemic penumbra leading to earlier hae-
modynamic normalisation.120,121 In addition, different
observational studies have evaluated blood pressure
levels following successful recanalisation in AIS
patients due to large vessel occlusion and have con-
sistently reported an inverse association between
increasing post-reperfusion blood pressures and good
functional outcomes at three months.122–124 They also
highlight, that systolic blood pressure levels
< 140mmHg post MT are related to the higher
odds of good functional outcome. Also, a single-
centre study has recently documented that spontane-
ous systolic blood pressure drop after MT is an early
predictor of dramatic neurological recovery (defined
as 8-point-reduction in baseline NIHSS-score or an
overall NIHSS  2 points at 24 h) in large vessel
occlusion patients that receive endovascular treat-
ment.125 There is no randomised data regarding
the safety and efficacy of induced hypertension in
large vessel occlusion patients who achieve success-
ful reperfusion following endovascular therapy.
Nevertheless, there are theoretical concerns against
drug-induced hypertension in large vessel occlusion
with complete recanalisation (in particular in
patients achieving mTICI 3 corresponding to com-
plete reperfusion without any parenchymal defects
even in distal vessels) following endovascular thera-
py. In particular, transcranial Doppler studies mon-
itoring cerebral haemodynamics of AIS patients in
real-time have shown that elevated flow velocities
following complete recanalisation of large vessel
occlusion may lead to hyperperfusion haemorrhage
within the area of infarcted brain tissue in large
vessel occlusion patients achieving mTICI 2 b/2c/3
grades following MT.126–128
Dynamic autoregulation-based blood pressure tar-
gets instead of fixed blood pressure thresholds hold
promise as a guide for individualising haemodynamic
management in AIS due to large vessel occlusion. In a
small observational study, a novel approach to define
the limits of autoregulation using near-infrared spec-
troscopy (NIRS) was proposed. Continuous non-
invasive NIRS monitoring in response to changes in
mean arterial pressure was found to identify and track
the patient-specific blood pressure range at which
autoregulation was optimally functioning in individual
patients after large vessel AIS.129
Recommendations
1. In patients with acute ischaemic stroke due to large vessel
occlusion undergoing mechanical thrombectomy (with or
without intravenous thrombolysis) we suggest keeping
blood pressure below 180/105mmHg during, and 24
hours after, mechanical thrombectomy. No specific
blood pressure lowering agent can be recommended.
Quality of evidence: Very low
Strength of recommendation: Weak "?
2. In patients with acute ischaemic stroke due to large vessel
occlusion we suggest against actively reducing systolic
blood pressure< 130mmHg during the first 24 hours
following successful mechanical thrombectomy
Quality of evidence: Moderate
Strength of recommendation: Weak #?
3. In patients with acute ischaemic stroke due to large vessel
occlusion undergoing treatment with mechanical throm-
bectomy (with or without intravenous thrombolysis) sys-
tolic blood pressure drops should be avoided.
Quality of evidence: Very low
Strength of recommendation: Strong ##
Expert consensus statement
In patients with acute ischaemic stroke due to large vessel
occlusion who achieve successful reperfusion defined as
modified Thrombolysis in Cerebral Infarction grade of 3
following mechanical thrombectomy we suggest against
induced hypertension. Vote 10 of 10
In patients with acute ischaemic stroke
not treated with reperfusion therapies
(intravenous thrombolysis or mechanical
thrombectomy) and with clinical
deterioration, does induced hypertension
by any vasopressor drug compared to no
drug improve outcome?
Analysis of current evidence
The hypertensive response seen in patients with AIS
has traditionally been viewed as a pathophysiological
response to ensure adequate cerebral perfusion in
patients with compromised cerebral circulation. The
rationale for pharmacologically inducing hypertension
is to maintain adequate cerebral perfusion especially in
patients with large vessel occlusion, fluctuating symp-
toms and low blood pressure who are not eligible for
reperfusion or where reperfusion has failed.
The Safety and Efficacy of Therapeutic Induced
HYPERTENSION (SETIN-HYPERTENSION)
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randomised 153 patients with major neurological deficit
(NIHSS-score 4–18) from non-cardioembolic stroke
aetiology, ineligibility for reperfusion therapy or pro-
gressive stroke. Progressive stroke was defined as
2-point increase in the NIHSS score, including an
increase in the motor score for the affected upper or
lower limbs during hospitalisation and the presence of
new lesions or infarct growth on DWI performed within
24 hour of aggravation.130 Patients with systolic blood
pressure >170mmHg at baseline were excluded. The
intervention group received treatment with intravenous
phenylephrine with a target of 20% increase in systolic
blood pressure from baseline. Induced hypertension was
associated with early neurologic improvement at 7 days
(OR:2.49, 95%CI: 1.25–4.96, p¼ 0.010) though, this did
not translate into functional improvement at 90 days
(shift analysis in mRS scores): unadjusted common OR
1.27, 95%CI: 0.72–2.22, p¼ 0.422). Mortality at 90 days
did not differ between the intervention group (1.3%) and
the control group (0%; p¼ 0.313). The rates of patients
with good functional outcome at 90 days tended to be
higher in the intervention group (75.0% vs. 63.2%,
p¼ 0.114). ICH on follow-up MRI was more prevalent
in the induced hypertension group (6.6% vs 0%,
p¼ 0.022), however the rates of sICH were similar in
the two groups (1.3% vs. 0%, p¼ 0.313).130 There are
several limitations to the SETIN-HYPERTENSION
trial. First, patients in the induced hypertension group
were younger, were more often included due to stroke
progression, had higher NIHSS scores and a higher rate
of large vessel occlusions. Second, due to the small
sample size and that the trial was conducted in Korea,
generalisability is questionable.
Table 7 provides details regarding the safety and
efficacy of blood pressure elevation using any vasopres-
sor drug compared to no vasopressor drug in patients
with AIS and clinical deterioration not eligible for
reperfusion treatment.
Additional information
In a pilot trial, 15 patients recruited within 7 days of
symptom onset, with> 20% diffusion – perfusion mis-
match on MRI and quantifiable, stable or worsening of
aphasia, hemispatial neglect and/or hemiparesis were
randomly assigned to induced hypertension with phen-
ylephrine or control.131 There was more improvement in
NIHSS scores in the induced hypertension group com-
pared to the control group on day 3 and on day 90.131
Since functional outcome was not assessed with mRS at
90 days the study was not included in our meta-analysis.
The Early Manipulation of Arterial Blood Pressure
in Acute Ischaemic Stroke (MAPAS) trial randomised
218 patients within 12 hours of acute ischaemic stroke
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within three ranges; Group 1: SBP target 140–
160mmHg, Group 2: SBP target 161–180mmHg,
and Group 3: SBP target 181–200mmHg.132 Overall,
systolic blood pressure was increased in 41% of the
patients. Norepinephrine was used to increase blood
pressure in 17% of patients in Group 1, 48% of
patients in Group 2 and 62% of patients in Group 3.
There was no difference between the groups in func-
tional outcome at 90 days. Adverse events (acute coro-
nary syndrome and bradycardia) were limited to group
2 (4%) and Group 3 (7.6%) and were associated with
norepinephrine infusion. There was also a significantly
higher sICH rate in Group 3.132
In addition, observational data from small pilot
studies indicate that phenylephrine induced hyper-
tension may be associated with neurological improve-
ment in patients with AIS due to large artery
atherosclerotic steno-occlusive disease or small vessel
occlusion.133–137
Recommendation
In patients with acute ischaemic stroke not treated with
reperfusion therapies (intravenous thrombolysis or mechan-
ical thrombectomy) who experience clinical deterioration,
we suggest against the routine use of vasopressor drugs to
increase blood pressure.
Quality of evidence: Very low 
Strength of recommendation: Weak ##
Expert consensus statement
In patients with acute ischaemic stroke not treated with
reperfusion therapies (intravenous thrombolysis or mechan-
ical thrombectomy) and with clinical deterioration where a
haemodynamic mechanism is suspected or shown to be
directly responsible for the deterioration, we suggest:
• stopping existing blood pressure lowering therapy,
• administering intravenous fluids and
• introducing non-pharmacological procedures to raise
blood pressure
before considering
• careful use of vasopressor agents to increase blood pres-
sure with close monitoring of blood pressure values.
Vote 10 of 10.
In patients with acute ischaemic stroke,
does continuing versus temporarily
stopping previous oral blood pressure
lowering therapy improve outcome?
Analysis of current evidence
Blood pressure lowering therapy is a key strategy for the
primary and secondary prevention of AIS and other seri-
ous cardiovascular events. However, it is unclear if con-
tinuingor stoppingpreviousoral antihypertensive agents
is beneficial in the AIS setting. Continuing prior antihy-
pertensive agents may improve blood pressure control,
however, may also lower blood pressure and worsen the
perfusion of the critical hypoperfused brain tissue.
One RCT examined the effect of continuing or stop-
ping previous blood pressure lowering therapy in AIS.
The Continue Or Stop post-Stroke Antihypertensives
Collaborative Study (COSSACS) was a UK multi-
centre, prospective, randomised, open, blinded-
endpoint trial.138 In this study 763 patients who had
acute stroke and were taking antihypertensive drugs
were enrolled within 48 h of stroke onset. Among the
overall group, 444 patients were included with AIS. In
the predetermined subgroup analysis of AIS patients in
COSSACS there was a benefit in death or dependency
at three months (mRS scores 3) in the continue group
versus the stop group (46 of 241 patients versus 55 of
203 in the stop group; relative risk reduction 0.70, 95%
CI 0.51–0.99; p¼ 0.045).138
ENOS was a multicentre, partial-factorial, rando-
mised trial. In this study, 4011 patients who had stroke
were enrolled within 48 h of stroke onset. Among the
overall group, 928 patients with AIS were randomised
to continueand904 to stopantihypertensive treatment.37
A meta-analysis of individual patient data from the
COSSACS and Efficacy of Nitric Oxide in Stroke
(ENOS) trial evaluated the effect of continuing versus
stopping previous blood pressure-lowering therapy on
death or dependency and included 2335 patients with
AIS. There were no significant associations between
continuing versus stopping previous blood pressure
lowering therapy and the odds of death or improved
functional outcome at 3–6months in the AIS sub-
group.139 Two trials37,138 were included in the meta-
Figure 5. The effect of continuing versus temporarily stopping previous blood pressure lowering therapy on mortality at three to six
months following symptom onset in patients with acute ischaemic stroke.
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analysis on continuing versus stopping previous blood
pressure lowering therapy. There were no significant
differences of continuing versus stopping previous
blood pressure lowering therapy on mortality (OR
1.25, 95% CI 0.98 – 1.60, p¼ 0.07, I2¼ 0%; Figure 5)
nor good functional outcome (mRS 0 – 2) (OR 0.95, 95
% CI 0.83 – 1.13, p¼ 0.56, I2¼ 0%; Figure 6).
Table 8 provides details regarding the safety and
efficacy of continuing versus temporarily stopping pre-
vious blood pressure lowering therapy in AIS patients
based on published and unpublished data from the
individual patient data meta-analysis.139
Additional information
When deciding to continue or stop previous antihyper-
tensive agents whether the patient has received reperfu-
sion treatment, premorbid blood pressure values and the
need for antihypertensive agents tomaintain blood pres-
sure within the recommended thresholds need to be con-
sidered. In case anantihypertensive is needed tomaintain
blood pressure values within the recommended range,
continuation of previous antihypertensive agents may
favour more stable blood pressure control. However,
the continuation of oral antihypertensive agents may
be challenging in patients with dysphagia and impaired
consciousness. The route of application depends on the
ability to swallow and/or the degree of consciousness.
Recommendation
In patients with acute ischaemic stroke, there is continued
uncertainty over the benefits and risks (advantages/disad-
vantages) of continuing versus temporarily stopping previ-
ous blood pressure lowering therapy.
Quality of evidence: Moderate
Strength of recommendation: -
Expert consensus statement
In patients with acute ischaemic stroke we suggest stopping
previous oral blood pressure lowering therapy in patients
with dysphagia until swallowing is restored or a nasogastric
tube is in place. Vote 10 of 10
In patients with acute intracerebral
haemorrhage, does intensive blood
pressure lowering with any vasodepressor
drug compared to control improve
outcome?
Analysis of current evidence
The rationale behind decreasing blood pressure in
acute spontaneous ICH is to reduce the driving force
of haematoma expansion and thereby to prevent fur-
ther clinical deterioration. Most haematoma expansion
takes place within the first three hours.140
The INTensive blood pressure reduction in Acute
Cerebral Haemorrhage trial (INTERACT); compared
intensive lowering with a target systolic blood pres-
sure of <140mmHg within 1 hour (intensive group)
with a moderate lowering with a target systolic blood
pressure of <180mmHg within 6 hours (standard
group) after spontaneous ICH.141 The trial recruited
404 patients. Blood pressure lowering drugs were
administered according to a “stepped intravenous pro-
tocol to lower blood pressure” which was “established
before the start of the study based on which drugs
were available in that country” with urapidil being
the most frequently used agent (47%). The primary
efficacy endpoint (the mean proportional change in
haematoma volume at 24 hours) was significantly
smaller in the intensive lowering group (13.7%) com-
pared to the standard group (36.3%, differ-
ence¼ 22.6%, 95% CI: 0.6–44.5%; p¼ 0.04).141
There was no difference in the risk of adverse
events.141
INTERACT-2 recruited 2839 patients using the
identical treatment protocol as the INTERACT trial.
There was no signficant difference in the primary out-
come (death or dependency at 90 days defined as mRS
scores of 3–6) (OR with intensive treatment, 0.87; 95%
CI:0.75–1.01; p¼ 0.06).21 However, the pre-defined
secondary endpoint (ordinal analysis of 3-month
mRS scores) showed significantly lower mRS scores
with intensive treatment (common OR for functional
worsening defined as 1-point increase across all mRS
scores 0.87; 95% CI: 0.77–1.00; p¼ 0.04). The rates of
Figure 6. The effect of continuing versus temporarily stopping previous blood pressure lowering therapy on good functional
outcome (defined as mRS scores 0–2) at three to six months following symptom onset in patients with acute ischaemic stroke.
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non-fatal serious adverse events did not differ between
the groups.21
The Antihypertensive Treatment of Acute Cerebral
Haemorrhage-II (ATACH-II) trial compared intensive
(target systolic blood pressure 111–140mmHg) with
moderate (target systolic blood pressure 140–
180mmHg) blood pressure lowering with intravenous
nicardipine in patients with spontaneous ICH within
4.5 hours of symptom onset.142 The trial recruited
1000 patients and there were no differences between
the intensive and moderate groups in primary endpoint
(death or disability at three months defined as mRS-
scores of 4–6): adjusted relative risk (RR): 1.04; 95%
CI: 0.85–1.27. There was a significantly higher rate of
renal adverse events within 7 days after randomisation
in the intensive treatment group (9.0% vs. 4.0%,
p¼ 0.002).142 A post-hoc-analysis of ATACH-II
showed a significant reduction on haematoma expan-
sion within 24 hours and a significantly better function-
al outcome at three months when blood pressure
lowering was initiated within 2 hours of symptom
onset.143
The Controlling Hypertension After Severe
Cerebrovascular Event (CHASE) trial included a
mixed population with either severe AIS or ICH
patients presenting with systolic blood pressure levels
ranging between 150mmHg and 210mmHg.50 The
trial compared an individualised blood pressure lower-
ing strategy with standard blood pressure lowering. In
the subgroup of ICH (n¼ 242), the rates of the prima-
ry endpoint (the proportion of patients with a poor
functional outcome at day 90 of enrolment defined
as mRS scores of 3–6) were similar in the standard
blood pressure lowering group (79/116; 68%) and in
the individualised blood pressure lowering group (80/
126; 63%).50 There was no difference in mortality rates
(12% vs. 13%).
The Controlling Hypertension and Hypotension
Immediately Post Stroke (CHHIPS) included a mixed
population of patients with AIS (n¼ 154) and ICH
(n¼ 25) presenting with systolic blood pressure higher
than 160mmHg on admission who were treated with
labetalol (n¼ 58), lisinopril (n¼ 58) or placebo
(n¼ 63). The primary endpoint (death or dependency
at 2weeks) occurred in 14 of 18 patients treated with
labetalol or lisinopril (“active treatment”) and 3 of 7
placebo patients in the ICH subgroup. Death occurred
in 2 and 0 patients in the active and placebo arms,
respectively.51
In the subgroup of 629 patients with ICH included
in ENOS, GTN was not associated with functional
worsening (defined as a 1-point increase across all
three-month mRS scores, shift analysis): adjusted
common OR: 1.04; 95%CI: 0.78–1.38). There was no
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(OR: 0.91; 95%CI: 0.55–1.55).144 In the subgroup of 61
ICH patients treated within 6 hours, GTN was associ-
ated with lower odds of functional worsening at three
months (adjusted common OR 0.19; 95% CI 0.06–0.59;
p¼ 0.004) and lower 3-month mortality rates (7% vs.
38%, p¼ 0.006).144
In the subgroup of 145 patients with confirmed ICH
included in the RIGHT-2 trial, patients in the GTN
group tended to have worse functional outcomes at
three months (adjusted common OR for 1-point
increase across all three-month mRS scores 1.87, 95%
CI: 0.98–3.57). More patients in the GTN died in hos-
pital (adjusted OR 2.26, 95%CI: 1.03–4.95), but there
was no difference in death at 90 days (OR 1.50, 95%CI:
0.86–2.62).29 Since treatment with GTN was initiated
in the ambulance prior to imaging whether these results
are due to chance, confounding or the true effect of
GTN remains uncertain.
Gupta and co-workers randomised 118 patients with
ICH within 72 hours of symptom onset to tight blood
pressure control if mean arterial pressure exceeded
115mmHg or to conventional blood pressure control
if mean arterial pressure 130mmHg. Patients were
randomised within 1 hour of admission and treatment
was continued for 72 hours.145 There was no difference
in the primary endpoint (mRS-scores of 3–6 at 90 days)
between the two treatment groups (OR: 0.70; 95%CI:
0.34–1.47).145
Koch and co-workers randomised 42 patients with
ICH within 8 hours of symptom onset to either aggres-
sive (mean arterial pressure< 110mmHg) or standard
treatment (mean arterial pressure 110–130mmHg).146
Treatment duration was 48 hours. The rates of the pri-
mary endpoint (neurological deterioration within the
first 48 hours) were similar in the aggressive (1/21)
and standard (2/21) treatment groups. There were
also no differences in 3-month mortality or haematoma
expansion (defined as an increase of more than 30% of
the initial ICH volume).146
In the subgroup analysis of 274 patients with ICH in
the SCAST trial, patients in the candesartan group had
significantly worse functional outcome (defined as
1-point increase across all six-month mRS scores),
adjusted common OR 1.61, 95% CI: 1.03–2.50.147
The Intracerebral Haemorrhage Acutely Decreasing
Arterial Pressure Trial (ICH-ADAPT) evaluated the
influence of systolic blood pressure lowering on cerebral
blood flow (CBF). Patients with acute ICH and systolic
blood pressure >150mmHg on admission, brain CT
within 24 hours after symptom onset and no contraindi-
cation to CT angiography were randomised to systolic
blood pressure target of<150mmHg (n¼ 39) compared
to a systolic blood pressure target of <180mmHg
(n¼ 36) to be reached within 1 hour of randomisa-
tion.148,149 At 2 hours, the mean systolic blood pressure
was significantly lower in the <150mmHg group.
However, the primary endpoint (perihaematomal rela-
tive CBF) was not different between the two treatment
groups. There were no significant differences in mortal-
ity rates at day 30: 18% in the <150mmHg group and
11% in the <180mmHg group, and no difference in
functional outcomes at 90 days.149
The Perioperative Antihypertensive Treatment in
Patients With Spontaneous Intracerebral
Haemorrhage (PATICH) was a single centre,
assessor-blinded RCT that investigated the effect of
peri-operative anti-hypertensive therapy. Adult
patients with imaging-proven (brain CT or MRI)
acute ICH, elevated systolic blood pressure (150–
220mmHg) and the need for surgery within 24 hours
after onset were randomised within 1 hour of admission
to an intensive treatment group (n¼ 100; systolic blood
pressure within the first hour after admission: 140–
160mmHg, intraoperatively: 120–140mmHg, after
Figure 7. The effect of intensive blood pressure lowering with any vasodepressor drug compared to control on mortality at three to
six months following symptom onset in patients with acute intracerebral haemorrhage.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































operation: 120–140mmHg for 7 days) or conservative
treatment group (n¼ 101; perioperative systolic blood
pressure: 140–180mmHg, intraoperatively systolic
blood pressure: 90–140mmHg).150 The primary end-
point was the incidence of re-haemorrhage within
7 days after randomisation “defined as a greater
postoperative haematoma volume, a difference of
5mL between the pre- and postoperative haematoma
volumes or a difference of 5mL in haematoma vol-
umes between the first postoperative computed tomog-
raphy and the subsequent computed tomography”. The
re-haemorrhage rates did not differ between the
Figure 8. The effect of intensive blood pressure lowering with any vasodepressor drug compared to control on mortality at three to
six months following symptom onset in in subgroups stratified by time to treatment (trials enrolling patients within 6 hours, trials
enrolling patients within 24 hours after exclusion of trials enrolling patients within 6 hours, and trials enrolling patients within 72 hours
after excluding trials enrolling within 24 hours).
Figure 9. The effect of intensive blood pressure lowering with any vasodepressor drug compared to control on good functional
outcome (defined as mRS scores 0–2 at three to six months following symptom onset) in patients with acute intracerebral
haemorrhage.
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intensive (11%) and conservative (14%) groups. The
mortality rates at 90 days were also similar.150
Twelve RCTs were included in the meta-analysis
of blood pressure lowering with any vasodepressor
drug compared with control on mortality at 3-6
months, and there were no differences between
the groups (OR 1.01 [95%CI: 0.86, 1.18]; I2¼ 0%;
Figure 7, Table 9).21,29,37,50,51,141,142,144,145–147,149,150
Treatment time window varied between 3 and
72 hours. Subgroup analyses of mortality according
to time to treatment revealed no significant
associations between blood pressure lowering and mor-
tality at three to six months at different time windows
(Figure 8).
Data on good functional outcome defined as mRS
scores of 0–2 at three to six months were available from
10 RCTs.21,29,50,141,142,144-147,150 Blood pressure lower-
ing with any vasodepressor was associated with no ben-
efit on good functional outcome (OR 1.05, 95%CI:
0.91–1.20; I2¼ 20%; Figure 9, Table 9) Subgroup anal-
yses of good functional outcome (mRS scores 0–2) at
three to six months according to treatment time
Figure 10. The effect of intensive blood pressure lowering with any vasodepressor drug compared to control on good functional
outcome (defined as mRS scores 0–2 at three to six months following symptom onset) in subgroups stratified by time to treatment
(trials enrolling patients within 6 hours, trials enrolling patients within 24 hours after exclusion of trials enrolling patients within
6 hours, and trials enrolling patients within 72 hours after excluding trials enrolling within 24 hours).
Figure 11. The effect of intensive blood pressure lowering with any vasodepressor drug compared to control on haematoma
expansion.
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window revealed no significant associations between
blood pressure lowering and good functional outcomes
at three to six months at different time windows
(Figure 10, Table 9).
Data on haematoma expansion were available from
5 RCTs.21,141,142,146,149 Overall, intensive blood pres-
sure lowering treatment did not reduce haematoma
expansion (RR¼ 0.84, 95%CI:0.62–1.13; I2¼ 41%
Figure 11, Table 9). In the subgroup analysis of trials
randomising ICH patients within 6 hours from symp-
tom onset (Figure 12, Table 9) intensive blood pressure
lowering was associated with lower likelihood of haema-
toma expansion: OR¼ 0.81;95%CI: 0.67–0.99;
I2¼ 45%. There was no marked effect of antihyperten-
sive treatment when time treatment window was
24hours (Figure 12). These data support a potential
biological effect of blood pressure lowering therapy on
haematoma expansion.
Acute renal injury has been described as serious
adverse event of intensive blood pressure lowering in
spontaneous ICH. Analysis of the four trials reported
that acute renal injury rates in the treatment arms
revealed no association between intensive blood pres-
sure lowering and acute renal injury in ICH (OR 0.87;
95%CI: 0.28–2.74, Table 9).
Table 9 provides the evidence profile regarding the
safety and efficacy of intensive blood pressure lowering
in acute ICH. The existing data is of moderate quality
and predominantly concerns conscious patients, who
do not require surgical intervention. Furthermore,
there are limited data on patients treated very early
from ICH onset (minutes to hours). Finally, it should
be noted that ATACH-II excluded patients with hae-
matoma volumes >60 cm3,142 while INTERACT-2
excluded patients if “they had a massive haematoma
with a poor prognosis, or if early surgery to evacuate
the haematoma was planned”.21 Thus, the presented
associations predominantly correspond to acute ICH
patients with small to moderate haematoma volumes.
Additional information
Burgess and co-workers performed a prospective
cohort study on 448 patients with acute spontaneous
ICH and looked at the effect of the extent of blood
lowering on the occurrence of acute renal injury in
patient with and without chronic kidney disease.151
The risk of acute renal injury was associated with
>90mmHg reduction of baseline systolic blood
pressure.
In order to achieve rapid and controlled blood pres-
sure lowering, drugs used need to be fast-acting with a
short half-life time to reduce the risk of excessive blood
pressure lowering. Most of the currently used antihy-
pertensives (urapidil, labetalol, esmolol, nicardipine)
do only partially fulfil these criteria. Clevidipine is a
calcium channel antagonist with a half-life time of
1.5minutes that may be effective in blood pressure con-
trol of patients with acute ICH. Graffagnino and co-
workers published a very small prospective case-series
of 35 patients with acute ICH treated with clevidi-
pine.152 Mean time to target pressure between 140
and 160mmHg was 5.5minutes and mean ICH
volume increase was negligible (0,01ml).
Figure 12. The effect of intensive blood pressure lowering with any vasodepressor drug compared to control on haematoma
expansion in subgroups stratified by time to treatment (trials enrolling patients within 6 hours, trials enrolling patients within 24 hours
after exclusion of trials enrolling patients within 6 hours).
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In conclusion, early (<6 hours from symptom) lower-
ing of blood pressure leads to a reduction of haematoma
expansion in acute ICHpatients.Haematoma expansion
is strongly and independently associated with adverse
functional outcome at three months in acute ICH.153
The question remains: Why does reduction of haema-
toma expansion not translate into a clinical benefit?
Our hypothesis is as follows: The clinical benefit in
ICH is primarily derived by preventing lesion increase
(¼ haematoma expansion). An individual patient data
meta-analysis of 5435 acute ICH patients identified two
strong predictors of haematoma expansion. First, the
time from onset to first brain CT and second, the
volume of baseline ICH.140Most haematoma expansion
occurred within the first three hours after onset of ICH.
The probability of haematoma expansion increased with
the volume of the initial lesion up to 75ml.140 In the five
RCTs on blood pressure lowering for hyperacute ICH,
the mean time from ICH onset to treatment in was
5.7 hours. This timeframe is at least 2 hours longer than
the time period where haematoma expansion most com-
monly occurs.21,141,142,146,149
The mean volume of the initial lesion in the five
RCTs was 14ml, which may be too small to show a
clinically meaningful change by preventing haematoma
expansion.21,141,142,146,149 Since the evidence available is
primarily from patients with small haematoma volume,
uncertainty remains regarding the effect of blood pres-
sure lowering in patients with large initial haematoma
volumes. Also, it should be noted that in addition to
haematoma expansion there are other factors impact-
ing 3-month functional outcome in acute ICH includ-
ing neurocritical care, location of baseline haematoma
volume, end-of-life health policies across different
countries and these factors may have moderated or
diluted the potential association of early (<6 h) inten-
sive blood pressure lowering and functional outcome at
three months.
A robust marker of ongoing bleeding, studied exten-
sively over the past years, is the CT angiography spot
sign.153,154 The spot sign is commonly assumed to rep-
resent continued bleeding (e.g., contrast extravasation
visualised on CTA after contrast bolus injection) from
ruptured vessels surrounding the initial haematoma.
The spot sign has been associated with both haema-
toma expansion and poor clinical outcomes in acute
ICH patients.155 SCORE-IT (Spot Sign Score in
Restricting ICH Growth) is a preplanned prospective
observational study nested in the ATACH-II RCT
including consecutive patients with primary ICH who
underwent a CT angiography within 8 hours from
onset.156 A total of 133 patients were included in this
preplanned analysis. Of these, 40% had a spot sign,
and 20% experienced haematoma expansion. After
adjustment for potential confounders, intensive blood
pressure treatment was not associated with a significant
reduction of haematoma expansion (relative risk: 0.83;
95%CI: 0.27–2.51; p¼ 0.74) or functional outcome
(relative risk of 90-day mRS score 4, 1.24; 95%CI:
0.53–2.91; p¼ 0.62) in spot sign–positive patients.
Recommendation
In patients with acute (<24 hours) intracerebral haemor-
rhage there is continued uncertainty over the benefits and
risks (advantages/disadvantages) of intensive blood pressure
lowering on functional outcome.
Quality of evidence: Moderate
Strength of recommendation: -
In patients with hyperacute (<6 hours) intracerebral hae-
morrhage, we suggest lowering blood pressure to below
140mmHg (and to keep it above 110mmHg) to reduce
haematoma expansion.
Quality of evidence: Moderate
Strength of recommendation: Weak "
Expert consensus statement
In patients with acute intracerebral haemorrhage, we sug-
gest initiating antihypertensive treatment as early as possible
and ideally within 2 hours of symptom onset. The decrease
of systolic blood pressure should not exceed 90mmHg
from baseline values. Vote 10 of 10.
In patients with acute intracerebral haemorrhage, we sug-
gest lowering blood pressure according to recommended
levels beyond 6 hours after onset of treatment for at least
24 hours and up to 72 hours to reduce haematoma expan-
sion. Vote 10 of 10.
In patients with acute intracerebral
haemorrhage, does continuing versus




Blood pressure lowering therapy is a key strategy for
the primary and secondary prevention of ICH and
other serious cardiovascular events. However, it is
unclear if it is better to continue or temporarily stop
prior ongoing antihypertensive agent(s) in the setting of
an acute ICH. One theoretical argument in favour of
continuing blood pressure lowering therapy in acute
ICH is related to more effective blood pressure control
that in turn may limit haematoma expansion. On the
other hand, it may be argued that continuing oral
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antihypertensive agents may worsen functional out-
come due to compromise in cerebral blood flow and
perihaematomal perfusion; furthermore, it may
increase the risk of aspiration pneumonia.
Analysis of current evidence. One RCT, ENOS, included
246 patients with acute ICH and elevated systolic blood
pressure (140–220mmHg) who were previously on
antihypertensive therapy. The patients were rando-
mised to continue or stop previous blood pressure low-
ering treatment for seven days.157 There was no
difference in mRS scores between the treatment
groups at day 90 (common OR for worse functional
outcome, defined by 1-point increase across all mRS
grades in the group that continued blood pressure low-
ering treatment 0.92; 95% CI: 0.45–1.89; p¼ 0.83).
There was no significant difference in mortality
between the 2 groups at day 90 (16.0% and 18.3% in
the continue versus stop groups, respectively).157 There
was no information on haematoma expansion.
A meta-analysis of individual patient data from
COSSACS and the ENOS trials evaluated the effect
of continuing versus stopping temporarily previous
blood pressure-lowering therapy on death or dependen-
cy in 2860 patients with acute stroke.139 The
meta-analysis indicated no significant association of
continuing versus stopping previous blood pressure
lowering therapy with the odds of death or the
improved functional outcome in the subgroup of
patients with ICH (Table 10).139 Two trials37,138 were
included in the meta-analysis on continuing versus
stopping previous blood pressure lowering therapy.
There were no significant differences between the con-
tinuing versus stopping previous blood pressure lower-
ing treatment on mortality (OR 0.93, 95% CI 0.50 –
1.72, p¼ 0.81, I2¼ 0%; Figure 13) nor on good func-
tional outcome (mRS 0–2) (OR 1.16, 95 % CI 0.68 –
1.98, p¼ 0.57, I2¼ 0%; Figure 14).
Table 10 provides details regarding the safety and
efficacy of continuing versus temporarily stopping pre-
vious blood-pressure lowering therapy in patients with
acute ICH based on published and unpublished data
from the individual patient data meta-analysis.139
Additional information
When deciding to continue or stop temporarily previ-
ous antihypertensive agents individual blood pressure
levels of ICH patients and the need to use or not to use
antihypertensive agents to maintain these levels within
the range recommended for patients with acute ICH
needs to be considered. The most common situation
in clinical practice is the need of a blood pressure low-
ering therapy to maintain blood pressure levels within
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previous antihypertensive agents may favour more
stable blood pressure control. However, the continua-
tion of oral antihypertensive agents may be challenging
in patients with dysphagia and impaired consciousness.
The route of application depends on the ability to swal-
low and/or the degree of consciousness.
Recommendation
In patients with acute intracerebral haemorrhage there is
continued uncertainty over the benefits and risks (advan-
tages/disadvantages) of continuing versus temporarily stop-
ping previous blood pressure lowering therapy.
Quality of evidence: Moderate
Strength of recommendation: -
Expert consensus statement
In patients acute intracerebral haemorrhage who need
blood pressure lowering therapy to maintain blood pressure
within the recommended range and who do not have swal-
lowing problems, we suggest continuation of prior oral anti-
hypertensive agents. Vote 10 of 10.
In patients with acute intracerebral haemorrhage who need
blood pressure lowering therapy to maintain blood pressure
within the recommended range and who have dysphagia or
decreased level of consciousness, we suggest temporarily
stopping previous oral hypertensive therapy and using intra-
venous antihypertensive agents until swallowing is restored
or a nasogastric tube is in place. Vote 10 of 10.
Discussion
This guideline document was developed using the
GRADE methodology and aims to assist physicians
in the management of blood pressure in AIS and
ICH. All recommendations and Expert consensus
statements are summarised in Table 11.
We have based all our recommendations on RCTs
or individual patient data meta-analyses whenever pos-
sible, but for certain PICO questions most of the evi-
dence is based on observational studies, with the
limitations this type of evidence entails. We provide
analyses in AIS and in ICH subgroups separately.
Although many of the trials covered in our guideline
enrolled patients with both ischaemic and haemor-
rhagic stroke subtypes, we believe that it is appropriate
to generate separate recommendations for these two
subtypes due to the differences in the pathophysiology.
In the AIS subgroup we have made specific recommen-
dations for patients undergoing acute reperfusion ther-
apies with intravenous alteplase, and/or endovascular
treatment. These are two specific settings where discus-
sions regarding appropriate blood pressure manage-
ment arise in most acute stroke departments daily.
The use of vasopressors is increasing in the manage-
ment of low blood pressure in AIS, especially in
patients undergoing endovascular procedure where
large drops in blood pressure is detrimental and in
patients with fluctuating symptoms with an assumed
haemodynamic aetiology. We therefore provided spe-
cific recommendations for these additional settings.
Figure 13. The effect of continuing versus temporarily stopping previous blood pressure lowering therapy on mortality at three to
six months following symptom onset in patients with acute intracerebral haemorrhage.
Figure 14. The effect of continuing versus temporarily stopping previous blood pressure lowering therapy on good functional
outcome (defined as mRS scores 0–2) at three to six months following symptom onset in patients with acute intracerebral
haemorrhage.
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For ICH we further classified our recommendations on
blood pressure management according to thresholds,
timing and agent/strategy.
The strengths of the current guideline are the sys-
tematic search of the literature and use of the GRADE
methodology to provide guidance for clinicians. Our
group conducted multiple analyses of the available
data using a strict meta-analytical approach.
Nevertheless, despite making our recommendations
based on randomised controlled data in different
stroke subgroups, the level of evidence is consistently
very low, low or moderate. This exemplifies the com-
plexity of blood pressure management in acute stroke
settings where epidemiological evidence, pathophysio-
logical evidence and data from RCTs are conflicting.
This also likely reflects the heterogeneity of the trials
included regarding timing of blood pressure manage-
ment, inclusion criteria and blood pressure lowering
strategies. To provide guidance for clinical practice
we made nine expert consensus statements in addition
to the official recommendations due to the equipoise in
clinical evidence. These statements have been voted on
among the working group. All the statements had
excellent agreement (10/10 in 8 statement and 9/10 in
one statement) among the group members.
Many questions regarding blood pressure manage-
ment in acute stroke remain unanswered. First, in both
patients with AIS and ICH blood pressure is a highly
individual parameter and the association between
blood pressure and outcome is likely to be multifacto-
rial. The “one-target fits all” may not be appropriate in
acute stroke settings, and future trials should consider
premorbid hypertension, baseline blood pressure
values and relative reductions in baseline blood pres-
sure rather than arbitrary absolute blood pressure tar-
gets. As shown in the evidence presented in these
guidelines, the detrimental effect of high blood pressure
on both short- and long-term outcome in AIS is not
altered by blood pressure lowering. There are also mul-
tiple stroke related factors contributing to elevated
blood pressure levels in AIS including ischaemic
stroke subtype, recanalisation status and collateral
flow that should be considered in the design of future
trials. In addition, future trials should differentiate
between the different blood pressure management
strategies before, during and after successful reperfu-
sion evaluating personalised autoregulation-oriented
blood pressure thresholds.
For patients with acute ICH we have shown effects
of blood pressure lowering on haematoma growth
within a narrow time window of 6 hours but not on
functional outcome. Overall, haematoma size in the
patients included in the trials was small and treatment
was in some of the trials initiated treatment up to
48 hours after symptom onset, which is likely too late
to influence outcome. There is also the possibility that
manipulating blood pressure is not effective enough
alone to influence functional outcome but may work
synergistically as part of a bundle of care that can carry
a greater impact on functional outcome. Future trials
should investigate the efficacy of blood pressure lower-
ing therapies in the hyperacute time window of first
6 hours following symptom onset in patients with
acute ICH and evaluate blood pressure lowering
agents that reduce blood pressure variability in addi-
tion to absolute blood pressure levels.
Plain language summary
The majority of patients with stroke either due to blood
clots (ischaemic stroke) or brain bleeds (intracerebral
haemorrhage) have high blood pressure both in the
ambulance and on admission to the hospital. We
know that high blood pressure in the acute phase of
stroke can lead to death, new strokes and poor func-
tional outcome. Despite this, we don’t know whether
we should treat high blood pressure as the damaged
brain might need higher blood pressure to ensure ade-
quate blood flow. The guideline authors provide ten
recommendation, the most important being:
1. Blood pressure in patients with suspected stroke
should not be treated in the ambulance
2. If the stroke is due to a blood clot in the arteries:
a. Blood pressure should not be treated unless the
blood pressure is very high (systolic blood pres-
sure >220mmHg) or if the patients can receive
treatment with clot-busting drugs (thrombolytics)
or clot-fishing (endovascular treatment).
b. Giving drugs to increase blood pressure should be
avoided in the majority of patients
c. If the patient is already under treatment with
blood pressure lowering drugs at the time of
admission these should be stopped in patients
who cannot swallow
3. If the stroke is caused by a brain bleed:
a. Elevated blood pressure should be treated as early
as possible after symptom onset
b. If patients are already under treatment with blood
pressure drugs these should be continued during
the hospital stay
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